Avicanna Announces Sponsorship of Pilot Phase II Clinical Study Osteoarthritis Pain

Core Insights - Avicanna Inc. has entered into a Sponsored Research Agreement to sponsor a randomized controlled trial (RCT) on the effectiveness of oral cannabis extracts for osteoarthritic pain, led by Dr. Hance Clarke [1][2] Group 1: Study Details - The RCT aims to determine the feasibility of a blinded, randomized, placebo-controlled, 3-arm trial of oral cannabinoids for improving pain interference in patients with hip and/or knee osteoarthritis [3] - The study is expected to start in Fall 2025 and will assess patient enrollment, protocol adherence, and data completeness [2][3] Group 2: Funding and Sponsorship - The RCT is funded by a grant from the Canadian Institutes of Health Research (CIHR) and is sponsored by Avicanna, which will provide its proprietary CBD and THC capsules produced under Good Manufacturing Practices (GMP) for the trial [4] Group 3: Company Overview - Avicanna is a biopharmaceutical company focused on the development and commercialization of cannabinoid-based products, with over thirty proprietary, evidence-based finished products [5] - The company operates multiple business pillars, including a medical cannabis formulary (RHO Phyto™), a medical cannabis care platform (MyMedi.ca), a pharmaceutical pipeline, and active pharmaceutical ingredients supplied by its subsidiary [5]